BR0015795A - éteres de 0-desmetil venlafaxina - Google Patents

éteres de 0-desmetil venlafaxina

Info

Publication number
BR0015795A
BR0015795A BR0015795-3A BR0015795A BR0015795A BR 0015795 A BR0015795 A BR 0015795A BR 0015795 A BR0015795 A BR 0015795A BR 0015795 A BR0015795 A BR 0015795A
Authority
BR
Brazil
Prior art keywords
alkyl
ethers
cycloalkyl
alkoxy
formula
Prior art date
Application number
BR0015795-3A
Other languages
English (en)
Inventor
John Patrick Yardley
Magid Abdel-Megid Abou-Gharbia
John William Ullrich
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0015795A publication Critical patent/BR0015795A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"éTERES DE O-DESMETIL VENLAFAXINA". A presente invenção refere-se aos éteres O-<244>-aciloxialquila do metabólito venlafaxina 4-[2-(dimetilamino-1-(1-hidroxiciclohexil)etil]fenol representado pela fórmula I, onde a configuração no centro esteriogênico (*) pode ser R, S, ou RS (o racemato); R~ 1~, é selecionado dentre C~ 1-6~ alquila, C~ 1-6~ alcóxi, C~ 3-6~ cicloalquila ou a porção (a) R~ 2~ é selecionado dentre H, ou C~ 1-6~ alquila; ou R~ 1~ e R~ 2~ podem estar concatinados de modo que (i) formem uma porção com a fórmula (b); R~ 3~ é selecionado dentre H ou C~ 1-6~ alquila; e R~ 4~ e R~ 5~ são independentemente selecionados dentre H, C~ 1-6~ alquila, C~ 3-6~ cicloalquila, C~ 1-6~ alcóxi, C~ 1-6~ tioalcóxi, -CN, OH, -CF~ 3~, -OCF~ 3~, halogênio, -NH~ 2~, -NO~ 2~ ou mono ou dialquilamino onde cada grupo alquila tem de 1-6 átomos de carbono, ou os sais farmaceuticamente aceitáveis ou hidratos destes; formas R, S, ou RS destes; bem como composições farmacêuticas e métodos para o tratamento de distúrbios do sistema nervoso central.
BR0015795-3A 1999-11-24 2000-11-21 éteres de 0-desmetil venlafaxina BR0015795A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44826899A 1999-11-24 1999-11-24
PCT/US2000/031895 WO2001038293A1 (en) 1999-11-24 2000-11-21 Ethers of o-desmethyl venlafaxine

Publications (1)

Publication Number Publication Date
BR0015795A true BR0015795A (pt) 2002-07-23

Family

ID=23779642

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015795-3A BR0015795A (pt) 1999-11-24 2000-11-21 éteres de 0-desmetil venlafaxina

Country Status (24)

Country Link
EP (1) EP1232141B1 (pt)
JP (1) JP2003514889A (pt)
KR (1) KR100843991B1 (pt)
CN (2) CN1198793C (pt)
AR (1) AR024498A1 (pt)
AT (1) ATE278659T1 (pt)
AU (1) AU767835B2 (pt)
BR (1) BR0015795A (pt)
CA (1) CA2391288A1 (pt)
CZ (1) CZ20021816A3 (pt)
DE (1) DE60014693T2 (pt)
DK (1) DK1232141T3 (pt)
ES (1) ES2228636T3 (pt)
HU (1) HUP0203594A2 (pt)
IL (2) IL149531A0 (pt)
MX (1) MXPA02005174A (pt)
NO (1) NO20022446L (pt)
NZ (1) NZ519130A (pt)
PL (1) PL202846B1 (pt)
PT (1) PT1232141E (pt)
SI (1) SI1232141T1 (pt)
TW (1) TWI268919B (pt)
WO (1) WO2001038293A1 (pt)
ZA (1) ZA200204986B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
KR101477154B1 (ko) * 2010-10-01 2014-12-29 산동 루예 파마슈티칼 컴파니 리미티드 4-[2-디메틸아미노-1-(1-하이드록시사이클로헥실)에틸]페닐 4-메틸벤조에이트 하이드로클로라이드의 다형체, 이의 제조 방법 및 이의 용도
CN103319373B (zh) * 2012-03-23 2017-09-19 浙江九洲药业股份有限公司 1‑[2‑氨基‑1‑(4‑苄氧基苯基)乙基]环己烷醇的制备方法及相关中间体

Also Published As

Publication number Publication date
CN1198793C (zh) 2005-04-27
DE60014693T2 (de) 2005-03-10
EP1232141B1 (en) 2004-10-06
NZ519130A (en) 2003-09-26
AU1783301A (en) 2001-06-04
CA2391288A1 (en) 2001-05-31
MXPA02005174A (es) 2002-11-07
CN1399626A (zh) 2003-02-26
AR024498A1 (es) 2002-10-02
DK1232141T3 (da) 2004-11-29
IL149531A (en) 2008-12-29
PL202846B1 (pl) 2009-07-31
SI1232141T1 (en) 2004-12-31
HUP0203594A2 (en) 2003-02-28
NO20022446D0 (no) 2002-05-23
CN1636559A (zh) 2005-07-13
JP2003514889A (ja) 2003-04-22
CZ20021816A3 (cs) 2002-08-14
PT1232141E (pt) 2004-12-31
HK1045835A1 (en) 2002-12-13
WO2001038293A1 (en) 2001-05-31
ES2228636T3 (es) 2005-04-16
IL149531A0 (en) 2002-11-10
NO20022446L (no) 2002-05-23
PL355171A1 (en) 2004-04-05
DE60014693D1 (en) 2004-11-11
AU767835B2 (en) 2003-11-27
ATE278659T1 (de) 2004-10-15
ZA200204986B (en) 2003-09-27
KR20030058931A (ko) 2003-07-07
EP1232141A1 (en) 2002-08-21
KR100843991B1 (ko) 2008-07-07
TWI268919B (en) 2006-12-21

Similar Documents

Publication Publication Date Title
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
BR0014733A (pt) Derivados éter biarìlico úteis como inibidores de recaptação de monoamina
BR9802439A (pt) Compostos de bispirazolaza, processo para sua preparação e tinturas capilares contendo esses compostos.
BRPI0415657A (pt) derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c
BR0009297A (pt) Composto, processo para produzir o mesmo,composição farmacêutica, método paraantagonizar hormÈnio de liberação degonadotropina em um mamìfero, e, uso de umcomposto
BRPI0515218A (pt) composto, composição farmacêutica, método para o tratamento de um mamìfero ou ser humano, método de uso do composto, novos intermediários, uso dos novos intermediários, processo para a preparação de um composto
BRPI0413533A (pt) derivados de malonamida que bloqueiam a atividade de gama-secretase
BR9711095A (pt) Composto de ciclopentano substituìdo, composição e método para inibir neuraminidase de vìrus influenza e método para tratar infecção de vìrus influenza
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BRPI0409227A (pt) composto, composição farmacêutica, uso de um composto, intermediário, e, processo para a preparação de um composto
BR9905788A (pt) Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados
BR0208111A (pt) Composto, utilização de um composto, processo de tratamento de distúrbios, processo para preparação de composto, composição farmacêutica que compreende o composto e processo de tratamento de obesidade
BR0214224A (pt) Derivado de 4,4-diflúor-1,2,3,4-tetrahidro-5h-1-benzazepina ou sal do mesmo
BRPI0410391A (pt) derivados (2-hidróxi-2-(4-hidróxi-3-hidroximetilfenil)-etilamino)- propilfenila como agonistas beta2
BR9915293A (pt) Compostos, método para preparar os mesmos, composições farmacêuticas, e métodos para preparar as mesmas, para tratar distúrbios de cns, e, para tratar ansiedade e/ou depressão.
BRPI0411285A (pt) composto, processo para preparar um composto formulação farmacêutica, uso de um composto, e, método de prevenção ou tratamento de distúrbios
BR9908125A (pt) Composto, composto dimérico, composição farmacêutica, uso do composto, processo compreendendo inibir células de câncer, e, processo terapêutico
BR0107958A (pt) Composição farmacêutica contendo pemetrexado juntamente com l-cisteìna monotrioglicerol ou ácido tioglicólico
BR0015795A (pt) éteres de 0-desmetil venlafaxina
AR002016A1 (es) Derivados de 3-fenilisoquinoleina-1-(2h)-ona, procedimiento para su preparacion y medicamento y composicion farmaceutica que los contienen.
BRPI0619213B8 (pt) composto precursor de composto orgânico marcado com haloênio radioativo
AR029795A1 (es) Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
BR9911611A (pt) Fenóis rádio-iodados para braquiterapia
BR0315971A (pt) Método para inibir o desenvolvimento de câncer por inibidores de sintase de ácido graxo
AR036351A1 (es) Isoxazolopiridinonas, el uso de las mismas para la fabricacion de un medicamento, composiciones y combinaciones farmaceuticas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.